FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of $34.06 million. The enterprise value is -$64.44 million.

Market Cap	34.06M
Enterprise Value	-64.44M

Important Dates

The last earnings date was Monday, November 10, 2025, after market close.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroGen has 4.05 million shares outstanding. The number of shares has increased by 1.55% in one year.

Current Share Class	4.05M
Shares Outstanding	4.05M
Shares Change (YoY)	+1.55%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	2.06%
Owned by Institutions (%)	16.35%
Float	3.58M

Valuation Ratios

The trailing PE ratio is 0.16.

PE Ratio	0.16
Forward PE	n/a
PS Ratio	4.10
Forward PS	5.39
PB Ratio	1.95
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 1.11.

Current Ratio	3.71
Quick Ratio	3.56
Debt / Equity	1.11
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.91

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-18.42%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-58.55%
Revenue Per Employee	$36,880
Profits Per Employee	$958,462
Employee Count	225
Asset Turnover	0.04
Inventory Turnover	2.78

Taxes

Income Tax	-88,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.20% in the last 52 weeks. The beta is 0.75, so FibroGen's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-17.20%
50-Day Moving Average	10.27
200-Day Moving Average	9.01
Relative Strength Index (RSI)	34.83
Average Volume (20 Days)	40,100

Short Selling Information

The latest short interest is 146,531, so 3.62% of the outstanding shares have been sold short.

Short Interest	146,531
Short Previous Month	104,776
Short % of Shares Out	3.62%
Short % of Float	4.09%
Short Ratio (days to cover)	4.90

Income Statement

In the last 12 months, FibroGen had revenue of $8.30 million and earned $215.65 million in profits. Earnings per share was $53.38.

Revenue	8.30M
Gross Profit	-30.35M
Operating Income	-59.16M
Pretax Income	-52.35M
Net Income	215.65M
EBITDA	-58.06M
EBIT	-59.16M
Earnings Per Share (EPS)	$53.38

Full Income Statement

Balance Sheet

The company has $117.98 million in cash and $19.47 million in debt, giving a net cash position of $98.50 million or $24.35 per share.

Cash & Cash Equivalents	117.98M
Total Debt	19.47M
Net Cash	98.50M
Net Cash Per Share	$24.35
Equity (Book Value)	17.49M
Book Value Per Share	-4.21
Working Capital	97.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$16.91 million and capital expenditures -$179,000, giving a free cash flow of -$17.09 million.

Operating Cash Flow	-16.91M
Capital Expenditures	-179,000
Free Cash Flow	-17.09M
FCF Per Share	-$4.22

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-712.89%
Pretax Margin	-630.84%
Profit Margin	2,598.87%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.55%
Shareholder Yield	-1.55%
Earnings Yield	633.11%
FCF Yield	-50.18%

Analyst Forecast

The average price target for FibroGen is $146.50, which is 1,639.91% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$146.50
Price Target Difference	1,639.91%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	-32.03%
EPS Growth Forecast (5Y)	-12.25%

Stock Forecasts

Stock Splits

The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:25.

Last Split Date	Jun 17, 2025
Split Type	Reverse
Split Ratio	1:25

Scores

FibroGen has an Altman Z-Score of -17.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.61
Piotroski F-Score	3